Viking\u2019s obesity flop, \u2018pharma to table\u2019 drug sales
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
On this week\u2019s episode of \u201cThe Readout LOUD\u201d: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Therapeutics<\/a> and the investor cult that embraces it, both of which performed a painful belly flop<\/a> this week.<\/p>\n Then, we\u2019ll dish on the growing \u201cpharm to table\u201d movement. That\u2019s the clever buzzphrase bandied around by Big Pharma insiders to promote plans that sell drugs directly to consumers \u2014 supposedly at lower costs that will make President Trump happy. Except as our cohost Elaine Chen reported this week<\/a>, these direct-to-consumer plans championed by Eli Lilly, Novo Nordisk, Bristol Myers Squibb, and others are unlikely to make drugs more affordable. We\u2019ll dig into the details.\u00a0<\/p>\n